Literature DB >> 22621796

Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.

Hector Malave1, Manuel Castro, Jaime Burkle, Szilard Voros, Thomas Dayspring, Robert Honigberg, Ray Pourfarzib.   

Abstract

Many patients with type 2 diabetes mellitus (T2DM) have relatively normal levels of low-density lipoprotein (LDL) cholesterol yet have increased risk for cardiovascular events. Distribution of lipoprotein subclasses in patients with T2DM who have achieved very low levels of LDL cholesterol (<50 mg/dl) or non-high-density lipoprotein (HDL) cholesterol (<80 mg/dl) have not been extensively examined. The aim of this study was to assess variations in lipoprotein particle concentration in patients with diabetes with "very low" LDL cholesterol and non-HDL cholesterol levels to elucidate the drivers of residual cardiovascular risk. Data were selected from a single large clinical laboratory database. Cases were patients with T2DM diagnosis codes (International Classification of Diseases, Ninth Revision, codes 250 to 250.93). Lipoprotein particle concentrations were analyzed using nuclear magnetic resonance spectroscopy. The Friedewald equation was used to calculate LDL cholesterol. Among the 1,970 patients with T2DM, the mean age was 61 years, and approximately 51% were men. At LDL cholesterol concentrations <50 mg/dl (triglyceride <150 mg/dl and HDL cholesterol >40 mg/dl), 16% had LDL particle concentrations <500 nmol/L, 70% had concentrations of 500 to 1,000 nmol/L, and 14% had concentrations >1,001 nmol/L. At non-HDL cholesterol levels <80 mg/dl, 8% had LDL particle concentrations <500 nmol/L, 67% had concentrations of 500 to 1,000 nmol/L, and 25% had concentrations >1,001 nmol/L. In conclusion, despite attainment of LDL cholesterol <50 mg/dl or non-HDL cholesterol <80 mg/dl, patients with diabetes exhibited significant variation in LDL particle levels, with most having LDL particle concentrations >500 nmol/L, suggesting the persistence of potential residual coronary heart disease risk.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621796     DOI: 10.1016/j.amjcard.2012.04.046

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

Authors:  Michael Clearfield; Melissa Pearce; Yasmin Nibbe; David Crotty; Alesia Wagner
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

Review 2.  Cardiovascular risk assessment and screening in diabetes.

Authors:  Yanglu Zhao
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

3.  Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial.

Authors:  Álvaro Hernáez; Alan T Remaley; Marta Farràs; Sara Fernández-Castillejo; Isaac Subirana; Helmut Schröder; Mireia Fernández-Mampel; Daniel Muñoz-Aguayo; Maureen Sampson; Rosa Solà; Magí Farré; Rafael de la Torre; María-Carmen López-Sabater; Kristiina Nyyssönen; Hans-Joachim F Zunft; María-Isabel Covas; Montserrat Fitó
Journal:  J Nutr       Date:  2015-07-01       Impact factor: 4.798

4.  Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes.

Authors:  Rachana D Shah; Barbara H Braffett; Jeanie B Tryggestad; Kara S Hughan; Ruban Dhaliwal; Kristen J Nadeau; Lorraine E Levitt Katz; Samuel S Gidding
Journal:  J Diabetes Complications       Date:  2022-01-03       Impact factor: 2.852

Review 5.  Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.

Authors:  Joe M Chehade; Margaret Gladysz; Arshag D Mooradian
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

6.  Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.

Authors:  Ngoc-Anh Le; Joanne E Tomassini; Andrew M Tershakovec; David R Neff; Peter W F Wilson
Journal:  J Am Heart Assoc       Date:  2015-10-20       Impact factor: 5.501

7.  The effects of high-intensity functional training on cardiometabolic risk factors and exercise enjoyment in men and women with metabolic syndrome: study protocol for a randomized, 12-week, dose-response trial.

Authors:  L E Smith; G P Van Guilder; L C Dalleck; N K Harris
Journal:  Trials       Date:  2022-03-01       Impact factor: 2.279

8.  Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA).

Authors:  Zhe Wang; Ani Manichukal; David C Goff; Samia Mora; Jose M Ordovas; Nicholas M Pajewski; Wendy S Post; Jerome I Rotter; Michele M Sale; Stephanie A Santorico; David Siscovick; Michael Y Tsai; Donna K Arnett; Stephen Rich; Alexis C Frazier-Wood
Journal:  Hum Genet       Date:  2017-03-28       Impact factor: 5.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.